Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Tarlatamab Earns UK Approval for Previously Treated ES-SCLC

January 6th 2025

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 12/29

January 4th 2025

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC

January 3rd 2025

China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.

Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC

January 2nd 2025

The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification

January 2nd 2025

China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.

European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC

January 2nd 2025

The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

OncLive’s December Roundup of Key FDA Approvals in Oncology

December 30th 2024

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

How a Never-Wavering Enthusiasm Changed Lung Cancer Care for the Better

December 30th 2024

As a female leader in a competitive oncology field, Solange Peters, MD, PhD, pushed through the barriers— climbed over them—and completely transformed lung cancer care with her collaborative spirit.

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC

December 30th 2024

Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC

December 24th 2024

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Defining Resectability in Stage III NSCLC: Addressing Key Controversies

December 24th 2024

Panelists discuss how the resectability of stage III non-small cell lung cancer tumors remains controversial, particularly regarding the role of surgery in multi-station N2 disease and the optimal sequencing of multimodality therapy.

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

December 23rd 2024

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

December 23rd 2024

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 12/15

December 21st 2024

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

December 21st 2024

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Dr Watson on the Use of Oncogene Analysis to Determine Clinically Relevant HER2, KRAS and MET Copy-Number Gain in NSCLC

December 20th 2024

Alec Watson, MD, discusses clinically relevant thresholds for HER2, KRAS, and MET gene copy number gain set by oncogene overlap analysis in NSCLC.

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

December 20th 2024

China's NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

December 20th 2024

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

December 18th 2024

The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.